CR-1301 is under clinical development by Conaris Research Institute and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CR-1301’s likelihood of approval (LoA) and phase transition for Intestinal Infection took place on 11 Feb 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CR-1301 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CR-1301 overview

CR-1301 is under development for the treatment of chronic intestinal infections. It is a intestinal microenvironment transfer or fecal microbiota filtrate transfer. The drug candidate is developed based on filtration technology.

Conaris Research Institute overview

Conaris Research Institute (Conaris) is a biotechnological company that offers preclinical and early clinical development services. The company provides drugs for various inflammatory indications. Its pipeline product candidates include CR12/01, CR12/02, CR13/01, CR15/01, FE999301, and conaskin tinktur. Conaris also develops fusion protein, gut microbiota modulator, anti-inflammatory small molecule, and anti-infectious drugs. The company offers services such as development of new drugs, physical and chemical characterization, lead optimization, lab scale production and GMP development. It also develops in-house technology platform and a network of associated partners for the requirements of drug development candidates. Conaris is headquartered in Kiel, Schleswig-Holstein, Germany.

Quick View CR-1301 LOA Data

Report Segments
  • Innovator
Drug Name
  • CR-1301
Administration Pathway
Therapeutic Areas
  • Gastrointestinal
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.